-
Bachmann MF, Jennings GT, 2010: Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns[J]. Nat Rev Immunol, 10, 787-796. doi: 10.1038/nri2868
-
Bolhassani A, Rafati S, 2008: Heat-shock proteins as powerful weapons in vaccine development[J]. Expert Rev Vaccines, 7, 1185-1199. doi: 10.1586/14760584.7.8.1185
-
Cai K, Feng JN, Wang Q, Li T, Shi J, Hou XJ, Gao X, Liu H, Tu W, Xiao L, Wang H, 2010: Fine mapping and interaction analysis of a linear rabies virus neutralizing epitope[J]. Microbes Infect, 12, 948-955. doi: 10.1016/j.micinf.2010.06.005
-
Chen C, Li J, Bi Y, Jia X, Meng S, Sun L, Liu W, 2012: Gp96 enhances the immunogenicity of subunit vaccine of porcine reproductive and respiratory syndrome virus[J]. Virus Res, 167, 162-172. doi: 10.1016/j.virusres.2012.04.011
-
Cliquet F, Aubert M, Sagne L, 1998: Development of a fluorescent antibody virus neutralisation test (FAVN test) for the quantitation of rabies-neutralising antibody[J]. J Immunol Methods, 212, 79-87. doi: 10.1016/S0022-1759(97)00212-3
-
Commission of Chinese Veterinary Pharmacopoeia. 2010. Veterinary Pharmacopoeia of the People's Republic of China. Chemical Industry Press: 163-168.
-
Crooks GE, Hon G, Chandonia JM, Brenner SE, 2004: WebLogo: a sequence logo generator[J]. Genome Res, 14, 1188-1190. doi: 10.1101/gr.849004
-
Degen WG, Jansen T, Schijns VE, 2003: Vaccine adjuvant technology: from mechanistic concepts to practical applications[J]. Expert Rev Vaccines, 2, 327-335. doi: 10.1586/14760584.2.2.327
-
Dey AK, Srivastava IK, 2011: Novel adjuvants and delivery systems for enhancing immune responses induced by immunogens[J]. Expert Rev Vaccines, 10, 227-251. doi: 10.1586/erv.10.142
-
Dietzschold B, Gore M, Marchadier D, Niu HS, Bunschoten HM, Otvos L Jr., Wunner WH, Ertl HC, Osterhaus AD, Koprowski H, 1990: Structural and immunological characterization of a linear virus-neutralizing epitope of the rabies virus glycoprotein and its possible use in a synthetic vaccine[J]. J Virol, 64, 3804-3809.
-
Dietzschold B, Li J, Faber M, Schnell M, 2008: Concepts in the pathogenesis of rabies[J]. Future Virol, 3, 481-490. doi: 10.2217/17460794.3.5.481
-
Guy B, 2007: The perfect mix: recent progress in adjuvant research[J]. Nat Rev Microbiol, 5, 505-517.
-
Houimel M, Dellagi K, 2009: Peptide mimotopes of rabies virus glycoprotein with immunogenic activity[J]. Vaccine, 27, 4648-4655. doi: 10.1016/j.vaccine.2009.05.055
-
Kaur M, Garg R, Singh S, Bhatnagar R, 2015: Rabies vaccines: where do we stand, where are we heading?[J]. Expert Rev Vaccines, 14, 369-381. doi: 10.1586/14760584.2015.973403
-
Koraka P, Bosch BJ, Cox M, Chubet R, Amerongen G, Lovgren-Bengtsson K, Martina BE, Roose J, Rottier PJ, Osterhaus AD, 2014: A recombinant rabies vaccine expressing the trimeric form of the glycoprotein confers enhanced immunogenicity and protection in outbred mice[J]. Vaccine, 32, 4644-4650. doi: 10.1016/j.vaccine.2014.06.058
-
Kundi M, 2007: New hepatitis B vaccine formulated with an improved adjuvant system[J]. Expert Rev Vaccines, 6, 133-140. doi: 10.1586/14760584.6.2.133
-
Li H, Nookala S, Re F, 2007: Aluminum Hydroxide Adjuvants Activate Caspase-1 and Induce IL-1 and IL-18 Release[J]. J Immunol, 178, 5271-5276. doi: 10.4049/jimmunol.178.8.5271
-
Li Y, Song H, Li J, Wang Y, Yan X, Zhao B, Zhang X, Wang S, Chen L, Qiu B, Meng S, 2011: Hansenula polymorpha expressed heat shock protein gp96 exerts potent T cell activation activity as an adjuvant[J]. J Biotechnol, 151, 343-349. doi: 10.1016/j.jbiotec.2010.12.006
-
Liu X, Yang Y, Sun Z, Chen J, Ai J, Dun C, Fu ZF, Niu X, Guo X, 2014: A recombinant rabies virus encoding two copies of the glycoprotein gene confers protection in dogs against a virulent challenge[J]. PLoS One, 9, e87105-. doi: 10.1371/journal.pone.0087105
-
Mansfield KL, Johnson N, Fooks AR, 2004: Identification of a conserved linear epitope at the N terminus of the rabies virus glycoprotein[J]. J Gen Virol, 85, 3279-3283. doi: 10.1099/vir.0.80362-0
-
Marissen WE, Kramer RA, Rice A, Weldon WC, Niezgoda M, Faber M, Slootstra JW, Meloen RH, Clijsters-van der Horst M, Visser TJ, Jongeneelen M, Thijsse S, Throsby M, de Kruif J, Rupprecht CE, Dietzschold B, Goudsmit J, Bakker AB, 2005: Novel rabies virus-neutralizing epitope recognized by human monoclonal antibody: fine mapping and escape mutant analysis[J]. J Virol, 79, 4672-4678. doi: 10.1128/JVI.79.8.4672-4678.2005
-
McCluskie MJ, Weeratna RD, 2001: Novel adjuvant systems[J]. Curr Drug Targets Infect Disord, 1, 263-271. doi: 10.2174/1568005014605991
-
Meloen RH, Langeveld JP, Schaaper WM, Slootstra JW, 2001: Synthetic peptide vaccines: unexpected fulfillment of discarded hope?[J]. Biologicals, 29, 233-236. doi: 10.1006/biol.2001.0298
-
Ni Y, Tominaga Y, Honda Y, Morimoto K, Sakamoto S, Kawai A, 1995: Mapping and characterization of a sequential epitope on the rabies virus glycoprotein which is recognized by a neutralizing monoclonal antibody, RG719[J]. Microbiol Immunol, 39, 693-702. doi: 10.1111/mim.1995.39.issue-9
-
Niederhauser S, Bruegger D, Zahno ML, Vogt HR, Peterhans E, Zanoni R, Bertoni G, 2008: A synthetic peptide encompassing the G5 antigenic region of the rabies virus induces high avidity but poorly neutralizing antibody in immunized animals[J]. Vaccine, 26, 6749-6753. doi: 10.1016/j.vaccine.2008.10.020
-
Pulmanausahakul R, Li J, Schnell MJ, Dietzschold B, 2008: The glycoprotein and the matrix protein of rabies virus affect pathogenicity by regulating viral replication and facilitating cell-to-cell spread[J]. J Virol, 82, 2330-2338. doi: 10.1128/JVI.02327-07
-
Rupprecht CE, Gibbons RV, 2004: Clinical practice[J]. Prophylaxis against rabies. N Engl J Med, 351, 2626-2635.
-
Takayama-Ito M, Inoue K, Shoji Y, Inoue S, Iijima T, Sakai T, Kurane I, Morimoto K, 2006: A highly attenuated rabies virus HEP-Flury strain reverts to virulent by single amino acid substitution to arginine at position 333 in glycoprotein[J]. Virus Res, 119, 208-215. doi: 10.1016/j.virusres.2006.01.014
-
Tao X, Han N, Guo Z, Tang Q, Rayner S, Liang G, 2013: Molecular characterization of China human rabies vaccine strains[J]. Virol Sin, 28, 116-123. doi: 10.1007/s12250-013-3314-9
-
Villarreal-Ramos B, 2009: Towards improved understanding of protective mechanisms induced by the BCG vaccine[J]. Expert Rev Vaccines, 8, 1531-1534. doi: 10.1586/erv.09.109
-
Wang S, Qiu L, Liu G, Li Y, Zhang X, Jin W, Gao GF, Kong X, Meng S, 2011: Heat shock protein gp96 enhances humoral and T cell responses, decreases Treg frequency and potentiates the anti-HBV activity in BALB/c and transgenic mice[J]. Vaccine, 29, 6342-6351. doi: 10.1016/j.vaccine.2011.05.008
-
World Organisation for Animal Health. 2013. Manual of Diagnostic Tests and Vaccines for Terrestrial Animals. OIE Terrestrial Manual: Chapter 2. 1. 13.
-
Xiao XX, Zhang Y, Liu JX, Wei QL, Yin XP, 2015: Immunoenhancement with flagellin as an adjuvant to whole-killed rabies vaccine in mice[J]. Arch Virol, 161, 685-691.
-
Xue XH, Zheng XX, Wang HL, Ma JZ, Li L, Gai WW, Wang TC, Yang ST, Xia XZ, 2014: An inactivated recombinant rabies CVS-11 virus expressing two copies of the glycoprotein elicits a higher level of neutralizing antibodies and provides better protection in mice[J]. Virus Genes, 48, 411-420. doi: 10.1007/s11262-014-1049-9
-
Yang L, Cen J, Xue Q, Li J, Bi Y, Sun L, Liu W, 2013: Identification of rabies virus mimotopes screened from a phage display peptidelibrary with purified dog anti-rabies virus serum IgG[J]. Virus Res, 174, 47-51. doi: 10.1016/j.virusres.2013.02.013
-
Yuan Z, Zhang S, Liu Y, Zhang F, Fooks AR, Li Q, Hu R, 2008: A recombinant pseudorabies virus expressing rabies virus glycoprotein: safety and immunogenicity in dogs[J]. Vaccine, 26, 1314-1321. doi: 10.1016/j.vaccine.2007.12.050
-
Zhang Y, Zhang S, Li W, Hu Y, Zhao J, Liu F, Lin H, Liu Y, Wang L, Xu S, Hu R, Shao H, Li L, 2016: A novel rabies vaccine based-on toll-like receptor 3 (TLR3) agonist PIKA adjuvant exhibiting excellent safety and efficacy in animal studies[J]. Virology, 489, 165-172. doi: 10.1016/j.virol.2015.10.029